It was a good news/bad news day for Regeneron Pharmaceuticals Inc., which reported Phase III data showing that IL-1 blocker Arcalyst (rilonacept) was successful in preventing gout attacks but failed to provide pain relief in the acute gout treatment setting. (BioWorld Today) Read More
